

Yehuda Carmeli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11330148/publications.pdf>

Version: 2024-02-01

223
papers

27,050
citations

9428

76
h-index

7043

159
g-index

225
all docs

225
docs citations

225
times ranked

22411
citing authors

#	ARTICLE	IF	CITATIONS
1	Analysis of four carbapenem-resistant <i>Acinetobacter baumannii</i> outbreaks using Fourier-transform infrared spectroscopy. <i>Infection Control and Hospital Epidemiology</i> , 2023, 44, 991-993.	1.0	6
2	In vivo fitness of carbapenem-resistant <i>Acinetobacter baumannii</i> strains in murine infection is associated with treatment failure in human infections. <i>Clinical Microbiology and Infection</i> , 2022, 28, 73-78.	2.8	1
3	Effect of a national policy of universal masking and uniform criteria for severe acute respiratory coronavirus virus 2 (SARS-CoV-2) exposure on hospital staff infection and quarantine. <i>Infection Control and Hospital Epidemiology</i> , 2022, 43, 757-763.	1.0	10
4	Carriage of vancomycin-resistant <i>Enterococcus faecium</i> in infants following an outbreak in the neonatal intensive care unit: time to clearance of carriage and use of molecular methods to detect colonization. <i>Infection Control and Hospital Epidemiology</i> , 2022, , 1-4.	1.0	0
5	Large-scale WGS of carbapenem-resistant <i>Acinetobacter baumannii</i> isolates reveals patterns of dissemination of ST clades associated with antibiotic resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 934-943.	1.3	5
6	A nationwide population-based study of <i>Escherichia coli</i> bloodstream infections: incidence, antimicrobial resistance and mortality. <i>Clinical Microbiology and Infection</i> , 2022, 28, 879.e1-879.e7.	2.8	16
7	Multicenter, Prospective Validation of a Phenotypic Algorithm to Guide Carbapenemase Testing in Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> Using the ERACE-PA Global Surveillance Program. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab617.	0.4	3
8	Hospital-Onset Bloodstream Infections Caused by Eight Sentinel Bacteria: A Nationwide Study in Israel, 2018–2019. <i>Microorganisms</i> , 2022, 10, 1009.	1.6	5
9	Unraveling the Diversity of Co-Colonization by CPE. <i>Microorganisms</i> , 2022, 10, 1292.	1.6	0
10	National Policy for Carbapenem-Resistant <i>Enterobacteriaceae</i> (CRE) Clearance and Discontinuation of Contact Precautions for CRE Carriers in Post-Acute Care Hospitals in Israel: Impact on Isolation-Days and New Acquisitions. <i>Clinical Infectious Diseases</i> , 2021, 72, 829-835.	2.9	4
11	<i>Citrobacter telavivum</i> sp. nov. with chromosomal mcr-9 from hospitalized patients. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 123-131.	1.3	28
12	Surgical antibiotic prophylaxis in patients colonized with multidrug-resistant Gram-negative bacteria: practical and conceptual aspects. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, i40-i46.	1.3	7
13	The effect of prophylaxis with ertapenem versus cefuroxime/metronidazole on intestinal carriage of carbapenem-resistant or third-generation-cephalosporin-resistant <i>Enterobacterales</i> after colorectal surgery. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1481-1487.	2.8	13
14	Excluded versus included patients in a randomized controlled trial of infections caused by carbapenem-resistant Gram-negative bacteria: relevance to external validity. <i>BMC Infectious Diseases</i> , 2021, 21, 309.	1.3	4
15	Antibiotic exposure and the risk of hospital-acquired diarrhoea and <i>Clostridioides difficile</i> infection: a cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2182-2185.	1.3	10
16	The Israeli national policy for discontinuation of isolation of carbapenem-resistant <i>Enterobacterales</i> carriers by carbapenemase type: a retrospective cohort study. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1518.e1-1518.e3.	2.8	3
17	The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant <i>Pseudomonas aeruginosa</i> . <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 2533-2541.	1.3	48
18	Evaluation of the MICRONAUT MIC-strip colistin assay for colistin susceptibility testing of carbapenem-resistant <i>Acinetobacter baumannii</i> and <i>Enterobacterales</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 2021, 100, 115391.	0.8	2

#	ARTICLE	IF	CITATIONS
19	Ceftazidime-Avibactam for the Treatment of Serious Gram-Negative Infections with Limited Treatment Options: A Systematic Literature Review. <i>Infectious Diseases and Therapy</i> , 2021, 10, 1989-2034.	1.8	55
20	Clinical and Microbiological Outcomes of Ceftazidime-Avibactam Treatment in Adults with Gram-Negative Bacteremia: A Subset Analysis from the Phase 3 Clinical Trial Program. <i>Infectious Diseases and Therapy</i> , 2021, 10, 2399-2414.	1.8	15
21	Elevated MICs of Susceptible Anti-Pseudomonal Cephalosporins in Non-Carbapenemase-Producing, Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> : Implications for Dose Optimization. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0120421.	1.4	6
22	Risk of SARS-CoV-2 transmission following exposure during dental treatment – A national cohort study. <i>Journal of Dentistry</i> , 2021, 113, 103791.	1.7	15
23	A multi-institutional outbreak of New Delhi metallo- β -lactamase-producing <i>Escherichia coli</i> with subsequent acquisition of the <i>Klebsiella pneumoniae</i> carbapenemase gene. <i>Infection Control and Hospital Epidemiology</i> , 2021, 42, 1124-1127.	1.0	1
24	Personalized Ertapenem Prophylaxis for Carriers of Extended-spectrum β -Lactamase-producing Enterobacteriaceae Undergoing Colorectal Surgery. <i>Clinical Infectious Diseases</i> , 2020, 70, 1891-1897.	2.9	22
25	<i>Clostridium difficile</i> associated disease and <i>Helicobacter pylori</i> seroprevalence: A case-control study. <i>Helicobacter</i> , 2020, 25, e12668.	1.6	2
26	Reply to Wilson et al. <i>Clinical Infectious Diseases</i> , 2020, 71, 1358-1359.	2.9	0
27	Colistin Resistance Development Following Colistin-Meropenem Combination Therapy Versus Colistin Monotherapy in Patients With Infections Caused by Carbapenem-Resistant Organisms. <i>Clinical Infectious Diseases</i> , 2020, 71, 2599-2607.	2.9	10
28	A National Intervention to Reduce Undesirable Urinary Tract Events in Internal Medicine Wards. <i>Infection Control and Hospital Epidemiology</i> , 2020, 41, s98-s98.	1.0	1
29	Enhanced Humoral Immune Responses against Toxin A and B of <i>Clostridium difficile</i> is Associated with a Milder Disease Manifestation. <i>Journal of Clinical Medicine</i> , 2020, 9, 3241.	1.0	1
30	Integrated chromosomal and plasmid sequence analyses reveal diverse modes of carbapenemase gene spread among <i>Klebsiella pneumoniae</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 25043-25054.	3.3	97
31	Rapid identification of capsulated <i>Acinetobacter baumannii</i> using a density-dependent gradient test. <i>BMC Microbiology</i> , 2020, 20, 285.	1.3	42
32	Elderly bedridden patients with dementia use over one quarter of resources in internal medicine wards in an Israeli hospital. <i>Israel Journal of Health Policy Research</i> , 2020, 9, 21.	1.4	6
33	Fourier Transform Infrared Spectroscopy Is a New Option for Outbreak Investigation: a Retrospective Analysis of an Extended-Spectrum-Beta-Lactamase-Producing <i>Klebsiella pneumoniae</i> Outbreak in a Neonatal Intensive Care Unit. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	1.8	37
34	A silent outbreak of vancomycin-resistant <i>Enterococcus faecium</i> in a neonatal intensive care unit. <i>Antimicrobial Resistance and Infection Control</i> , 2020, 9, 87.	1.5	12
35	Metagenomic Characterization of Gut Microbiota of Carriers of Extended-Spectrum Beta-Lactamase or Carbapenemase-Producing Enterobacteriaceae Following Treatment with Oral Antibiotics and Fecal Microbiota Transplantation: Results from a Multicenter Randomized Trial. <i>Microorganisms</i> , 2020, 8, 941.	1.6	21
36	In vivo Fitness of <i>Acinetobacter baumannii</i> Strains in Murine Infection Is Associated with International Lineage II-rep-2 and International Lineage III Clones Showing High Case Fatality Rates in Human Infections. <i>Microorganisms</i> , 2020, 8, 847.	1.6	5

#	ARTICLE	IF	CITATIONS
37	Detecting carbapenem-resistant <i>Acinetobacter baumannii</i> (CRAB) carriage: Which body site should be cultured?. <i>Infection Control and Hospital Epidemiology</i> , 2020, 41, 965-967.	1.0	17
38	Performance of Rapid Polymyxin _{â„} NP and Rapid Polymyxin _{â„} Acinetobacter for the detection of polymyxin resistance in carbapenem-resistant <i>Acinetobacter baumannii</i> and Enterobacterales. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1484-1490.	1.3	6
39	Reply to Apisarnthanarak and Apisarnthanarak. <i>Clinical Infectious Diseases</i> , 2020, 71, 2025-2025.	2.9	0
40	Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1185-1191.	2.8	46
41	Quantifying antibiotic impact on within-patient dynamics of extended-spectrum beta-lactamase resistance. <i>ELife</i> , 2020, 9, .	2.8	21
42	Utilising sigmoid models to predict the spread of antimicrobial resistance at the country level. <i>Eurosurveillance</i> , 2020, 25, .	3.9	3
43	Success of a National Intervention in Controlling Carbapenem-resistant Enterobacteriaceae in Israel's Long-term Care Facilities. <i>Clinical Infectious Diseases</i> , 2019, 68, 964-971.	2.9	26
44	Likelihood of persistent carriage of carbapenem-resistant <i>Acinetobacter baumannii</i> on readmission in previously identified carriers. <i>Infection Control and Hospital Epidemiology</i> , 2019, 40, 1188-1190.	1.0	4
45	External validation of the INCREMENT-CPE mortality score in a carbapenem-resistant <i>Klebsiella pneumoniae</i> bacteraemia cohort: the prognostic significance of colistin resistance. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 442-448.	1.1	11
46	Trends in antimicrobial resistance in Israel, 2014-2017. <i>Antimicrobial Resistance and Infection Control</i> , 2019, 8, 96.	1.5	15
47	Zero or More: Methodological Challenges of Counting and Estimating Deaths Related to Antibiotic-resistant Infections. <i>Clinical Infectious Diseases</i> , 2019, 69, 2029-2034.	2.9	9
48	Droplet aerosol dissemination of carbapenem-resistant <i>Acinetobacter baumannii</i> surrounding ventilated patients. <i>Infection Control and Hospital Epidemiology</i> , 2019, 40, 365-367.	1.0	9
49	Carriage of Extended-spectrum Beta-lactamase-producing Enterobacteriaceae and the Risk of Surgical Site Infection After Colorectal Surgery: A Prospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2019, 68, 1699-1704.	2.9	44
50	Treatment Outcomes of Colistin- and Carbapenem-resistant <i>Acinetobacter baumannii</i> Infections: An Exploratory Subgroup Analysis of a Randomized Clinical Trial. <i>Clinical Infectious Diseases</i> , 2019, 69, 769-776.	2.9	83
51	Antimicrobial use trends, Israel, 2012 to 2017. <i>Eurosurveillance</i> , 2019, 24, .	3.9	12
52	The possibility of transmitting infections with vaginal ultrasound probes: why the guidelines must be met. <i>Israel Medical Association Journal</i> , 2019, 21, 568-569.	0.1	0
53	Colistin versus colistin plus meropenem for severe infections Authors' reply. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 495-496.	4.6	1
54	Comparison of Predictors and Mortality Between Bloodstream Infections Caused by ESBL-Producing <i>Escherichia coli</i> and ESBL-Producing <i>Klebsiella pneumoniae</i> . <i>Infection Control and Hospital Epidemiology</i> , 2018, 39, 660-667.	1.0	49

#	ARTICLE	IF	CITATIONS
55	Risk factors for recurrent <i>Clostridium difficile</i> infection in a tertiary hospital in Israel. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018, 37, 1281-1288.	1.3	10
56	Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 391-400.	4.6	400
57	Lessons From an Outbreak of Varicella Infection in Pediatric Hemato-oncology Patients. <i>Pediatric Infectious Disease Journal</i> , 2018, 37, 649-653.	1.1	13
58	Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 318-327.	4.6	3,672
59	<i>Clostridium difficile</i> fecal toxin level is associated with disease severity and prognosis. <i>United European Gastroenterology Journal</i> , 2018, 6, 773-780.	1.6	25
60	The Association Between Empirical Antibiotic Treatment and Mortality in Severe Infections Caused by Carbapenem-resistant Gram-negative Bacteria: A Prospective Study. <i>Clinical Infectious Diseases</i> , 2018, 67, 1815-1823.	2.9	29
61	Does <i>Acinetobacter baumannii</i> Serve as a Source for bla _{NDM} Dissemination into <i>Enterobacteriaceae</i> in Hospitalized Patients?. <i>Microbial Drug Resistance</i> , 2018, 24, 150-153.	0.9	9
62	Israeli National Policy for Carbapenem-Resistant <i>Enterobacteriaceae</i> Screening, Carrier Isolation and Discontinuation of Isolation. <i>Infection Control and Hospital Epidemiology</i> , 2018, 39, 85-89.	1.0	30
63	The impact of antibiotic use on transmission of resistant bacteria in hospitals: Insights from an agent-based model. <i>PLoS ONE</i> , 2018, 13, e0197111.	1.1	55
64	Estimating the number of infections caused by antibiotic-resistant <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> in 2014: a modelling study. <i>The Lancet Global Health</i> , 2018, 6, e969-e979.	2.9	89
65	Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum-β-lactamase-producing <i>Enterobacteriaceae</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, dkw513.	1.3	46
66	Epidemiology and control measures of outbreaks due to Antibiotic-Resistant organisms in Europe (EMBARGO): a systematic review protocol. <i>BMJ Open</i> , 2017, 7, e013634.	0.8	9
67	Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing <i>Enterobacteriaceae</i> (INCREMENT): a retrospective cohort study. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 726-734.	4.6	367
68	Evolution and dissemination of the <i>Klebsiella pneumoniae</i> clonal group 258 throughout Israeli post-acute care hospitals, 2008-2013. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2219-2224.	1.3	16
69	Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by Carbapenem-Resistant Organisms. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	149
70	Incidence and Risk Factors for Community and Hospital Acquisition of <i>Clostridium difficile</i> Infection in the Tel Aviv Sourasky Medical Center. <i>Infection Control and Hospital Epidemiology</i> , 2017, 38, 912-920.	1.0	17
71	Carbapenem-Resistant <i>Enterobacteriaceae</i> : A Strategic Roadmap for Infection Control. <i>Infection Control and Hospital Epidemiology</i> , 2017, 38, 580-594.	1.0	74
72	Combination therapy for bloodstream infections with carbapenemase-producing <i>Enterobacteriaceae</i> – Authors' reply. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 1020-1021.	4.6	10

#	ARTICLE	IF	CITATIONS
73	The Impact of a Carbapenem-Resistant Enterobacteriaceae Outbreak on Facilitating Development of a National Infrastructure for Infection Control in Israel. <i>Clinical Infectious Diseases</i> , 2017, 65, 2144-2149.	2.9	12
74	Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study. <i>International Journal of Antimicrobial Agents</i> , 2017, 50, 664-672.	1.1	8
75	Gentamicin- and Ciprofloxacin-Resistant Enterobacteriaceae in Cattle Farms in Israel: Risk Factors for Carriage and the Effect of Microbiological Methodology on the Measured Prevalence. <i>Microbial Drug Resistance</i> , 2017, 23, 660-665.	0.9	1
76	Occurrence of carbapenemase-producing <i>Klebsiella pneumoniae</i> and <i>Escherichia coli</i> in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 153-163.	4.6	522
77	Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β -Lactamase-Producing Enterobacteriaceae: Results From the INCREMENT Cohort. <i>Clinical Infectious Diseases</i> , 2017, 65, 1615-1623.	2.9	43
78	A mathematical model of <i>Clostridium difficile</i> transmission in medical wards and a cost-effectiveness analysis comparing different strategies for laboratory diagnosis and patient isolation. <i>PLoS ONE</i> , 2017, 12, e0171327.	1.1	6
79	Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol. <i>BMJ Open</i> , 2016, 6, e009956.	0.8	41
80	Risk Factors for Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae (CP-CRE) Acquisition Among Contacts of Newly Diagnosed CP-CRE Patients. <i>Infection Control and Hospital Epidemiology</i> , 2016, 37, 1219-1225.	1.0	33
81	Dissemination of the <i>bla</i> _{KPC} gene by clonal spread and horizontal gene transfer: comparative study of incidence and molecular mechanisms. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2143-2146.	1.3	33
82	Prevalence and risk factors for carriage of extended-spectrum β -lactamase-producing Enterobacteriaceae among patients prior to bowel surgery. <i>Diagnostic Microbiology and Infectious Disease</i> , 2016, 85, 377-380.	0.8	12
83	A Multinational, Preregistered Cohort Study of β -Lactam/ β -Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum- β -Lactamase-Producing Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4159-4169.	1.4	137
84	Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and <i>Pseudomonas aeruginosa</i> complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 661-673.	4.6	327
85	A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae. <i>Mayo Clinic Proceedings</i> , 2016, 91, 1362-1371.	1.4	89
86	Molecular types and antimicrobial susceptibility patterns of <i>Clostridium difficile</i> isolates in different epidemiological settings in a tertiary care center in Israel. <i>Diagnostic Microbiology and Infectious Disease</i> , 2016, 86, 450-454.	0.8	7
87	Ceftazidime-avibactam in ceftazidime-resistant infections. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 997-998.	4.6	4
88	Outbreak of adenovirus type 55 infection in Israel. <i>Journal of Clinical Virology</i> , 2016, 78, 31-35.	1.6	33
89	Draft Genome Sequences of Two Multidrug-Resistant Extended-Spectrum- β -Lactamase-Producing <i>Klebsiella pneumoniae</i> Strains Causing Bloodstream Infections. <i>Genome Announcements</i> , 2016, 4, .	0.8	1
90	Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1672-1680.	1.3	41

#	ARTICLE	IF	CITATIONS
91	Comparative Study of a Novel Biochemical Assay, the Rapidec Carba NP Test, for Detecting Carbapenemase-Producing Enterobacteriaceae. <i>Journal of Clinical Microbiology</i> , 2016, 54, 453-456.	1.8	22
92	Efficacy of dalbavancin in the treatment of MRSA rat sternal osteomyelitis with mediastinitis. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 460-463.	1.3	30
93	Cost Analysis of an Intervention to Prevent Methicillin-Resistant <i>Staphylococcus Aureus</i> (MRSA) Transmission. <i>PLoS ONE</i> , 2015, 10, e0138999.	1.1	10
94	Incidence of Carbapenem-Resistant Gram Negatives in Italian Transplant Recipients: A Nationwide Surveillance Study. <i>PLoS ONE</i> , 2015, 10, e0123706.	1.1	68
95	Effect of Resistance Mechanisms on the Inoculum Effect of Carbapenem in <i>Klebsiella pneumoniae</i> Isolates with Borderline Carbapenem Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5014-5017.	1.4	33
96	Prevalence and risk factors for colonization with methicillin resistant <i>Staphylococcus aureus</i> and other <i>Staphylococci</i> species in hospitalized and farm horses in Israel. <i>Preventive Veterinary Medicine</i> , 2015, 122, 135-144.	0.7	17
97	Prevalence, Risk Factors, and Transmission Dynamics of Extended-Spectrum- β -Lactamase-Producing Enterobacteriaceae: a National Survey of Cattle Farms in Israel in 2013. <i>Journal of Clinical Microbiology</i> , 2015, 53, 3515-3521.	1.8	24
98	Persistence of <i>Klebsiella pneumoniae</i> ST258 as the predominant clone of carbapenemase-producing Enterobacteriaceae in post-acute-care hospitals in Israel, 2008-13. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 89-92.	1.3	54
99	Mix and match of KPC-2 encoding plasmids in Enterobacteriaceae-comparative genomics. <i>Diagnostic Microbiology and Infectious Disease</i> , 2014, 79, 255-260.	0.8	34
100	An Ongoing National Intervention to Contain the Spread of Carbapenem-Resistant Enterobacteriaceae. <i>Clinical Infectious Diseases</i> , 2014, 58, 697-703.	2.9	183
101	Infection control and prevention measures to reduce the spread of vancomycin-resistant enterococci in hospitalized patients: a systematic review and meta-analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1185-1192.	1.3	98
102	Emergence of VIM-producing <i>Aeromonas caviae</i> in Israeli hospitals. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1211-1214.	1.3	23
103	Biofilm formation and susceptibility to gentamicin and colistin of extremely drug-resistant KPC-producing <i>Klebsiella pneumoniae</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1027-1034.	1.3	63
104	Carbapenem-resistant Enterobacteriaceae: biology, epidemiology, and management. <i>Annals of the New York Academy of Sciences</i> , 2014, 1323, 22-42.	1.8	173
105	Development and validation of a multiplex PCR assay for identification of the epidemic ST-258/512 KPC-producing <i>Klebsiella pneumoniae</i> clone. <i>Diagnostic Microbiology and Infectious Disease</i> , 2014, 78, 12-15.	0.8	31
106	A National Intervention to Prevent the Spread of Carbapenem-Resistant Enterobacteriaceae in Israeli Post-Acute Care Hospitals. <i>Infection Control and Hospital Epidemiology</i> , 2014, 35, 802-809.	1.0	43
107	Combination therapy for carbapenem-resistant Gram-negative bacteria. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2305-2309.	1.3	179
108	Geographical Variability in the Likelihood of Bloodstream Infections Due to Gram-Negative Bacteria: Correlation with Proximity to the Equator and Health Care Expenditure. <i>PLoS ONE</i> , 2014, 9, e114548.	1.1	42

#	ARTICLE	IF	CITATIONS
109	Effect of an Investigational Vaccine for Preventing Staphylococcus aureus Infections After Cardiothoracic Surgery. JAMA - Journal of the American Medical Association, 2013, 309, 1368.	3.8	304
110	Systematic Review and Meta-Analysis of <i>In Vitro</i> Synergy of Polymyxins and Carbapenems. Antimicrobial Agents and Chemotherapy, 2013, 57, 5104-5111.	1.4	202
111	Epidemiological and Microbiological Characteristics of an Outbreak Caused by OXA-48-Producing Enterobacteriaceae in a Neonatal Intensive Care Unit in Jerusalem, Israel. Journal of Clinical Microbiology, 2013, 51, 2926-2930.	1.8	36
112	Epidemiological Interpretation of Studies Examining the Effect of Antibiotic Usage on Resistance. Clinical Microbiology Reviews, 2013, 26, 289-307.	5.7	141
113	Detection of the plasmid-mediated KPC-2 carbapenem-hydrolysing enzyme in three unusual species of the Enterobacteriaceae family in Israel. Journal of Antimicrobial Chemotherapy, 2013, 68, 719-720.	1.3	21
114	A Swordless Knight: Epidemiology and Molecular Characteristics of the <i>bla</i> _{KPC} -Negative Sequence Type 258 Klebsiella pneumoniae Clone. Journal of Clinical Microbiology, 2012, 50, 3180-3185.	1.8	37
115	Controlling Hospital-Acquired Infection due to Carbapenem-Resistant Enterobacteriaceae (CRE)., 2012, , 105-115.		1
116	Laboratory and Clinical Evaluation of Screening Agar Plates for Detection of Carbapenem-Resistant Enterobacteriaceae from Surveillance Rectal Swabs. Journal of Clinical Microbiology, 2011, 49, 2239-2242.	1.8	106
117	Containment of a Country-wide Outbreak of Carbapenem-Resistant Klebsiella pneumoniae in Israeli Hospitals via a Nationally Implemented Intervention. Clinical Infectious Diseases, 2011, 52, 848-855.	2.9	379
118	Predictors of Rectal Carriage of Carbapenem-Resistant Enterobacteriaceae (CRE) among Patients with Known CRE Carriage at Their Next Hospital Encounter. Infection Control and Hospital Epidemiology, 2011, 32, 497-503.	1.0	64
119	Carbapenem-Resistant <i>Klebsiella pneumoniae</i> in Post-Acute-Care Facilities in Israel. Infection Control and Hospital Epidemiology, 2011, 32, 845-853.	1.0	91
120	Laboratory evaluation of the CHROMagar KPC medium for identification of carbapenem-nonsusceptible Enterobacteriaceae. Diagnostic Microbiology and Infectious Disease, 2011, 70, 565-567.	0.8	27
121	The effects of group 1 versus group 2 carbapenems on imipenem-resistant Pseudomonas aeruginosa: an ecological study. Diagnostic Microbiology and Infectious Disease, 2011, 70, 367-372.	0.8	42
122	Pseudomonas aeruginosa bacteremia upon hospital admission: risk factors for mortality and influence of inadequate empirical antimicrobial therapy. Diagnostic Microbiology and Infectious Disease, 2011, 71, 38-45.	0.8	35
123	Dissemination of the Klebsiella pneumoniae Carbapenemase in the Health Care Settings: Tracking the Trails of an Elusive Offender. MBio, 2011, 2, .	1.8	13
124	Plasmid-encoded OXA-48 carbapenemase in Escherichia coli from Israel. Journal of Antimicrobial Chemotherapy, 2011, 66, 672-673.	1.3	42
125	Introduction of OXA-48-producing Enterobacteriaceae to Israeli hospitals by medical tourism. Journal of Antimicrobial Chemotherapy, 2011, 66, 2763-2766.	1.3	63
126	A Call for Action: The Application of the International Health Regulations to the Global Threat of Antimicrobial Resistance. PLoS Medicine, 2011, 8, e1001022.	3.9	67

#	ARTICLE	IF	CITATIONS
127	Molecular Epidemiology, Sequence Types, and Plasmid Analyses of KPC-Producing <i>Klebsiella pneumoniae</i> Strains in Israel. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 3002-3006.	1.4	79
128	Transfer of Carbapenem-Resistant Plasmid from <i>Klebsiella pneumoniae</i> ST258 to <i>Escherichia coli</i> in Patient. <i>Emerging Infectious Diseases</i> , 2010, 16, 1014-1017.	2.0	126
129	Plasmid pKpQIL encoding KPC-3 and TEM-1 confers carbapenem resistance in an extremely drug-resistant epidemic <i>Klebsiella pneumoniae</i> strain. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 243-248.	1.3	83
130	The Pivotal Role of Long-Term Care Facilities in the Epidemiology of <i>Acinetobacter baumannii</i> : Another Brick in the Wall. <i>Clinical Infectious Diseases</i> , 2010, 50, 1617-1618.	2.9	16
131	National Multicenter Study of Predictors and Outcomes of Bacteremia upon Hospital Admission Caused by <i>Enterobacteriaceae</i> Producing Extended-Spectrum β -Lactamases. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 5099-5104.	1.4	125
132	How to stem the tide of carbapenemase-producing <i>Enterobacteriaceae</i> ?: proactive versus reactive strategies. <i>Current Opinion in Infectious Diseases</i> , 2010, 23, 327-331.	1.3	63
133	Treatment with Fluoroquinolones or with β -Lactam- β -Lactamase Inhibitor Combinations Is a Risk Factor for Isolation of Extended-Spectrum β -Lactamase-Producing <i>Klebsiella</i> Species in Hospitalized Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 2010-2016.	1.4	70
134	Complete Nucleotide Sequence of KPC-3-Encoding Plasmid pKpQIL in the Epidemic <i>Klebsiella pneumoniae</i> Sequence Type 258. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 4493-4496.	1.4	107
135	Carbapenem-Resistant KPC-2-Producing <i>Escherichia coli</i> in a Tel Aviv Medical Center, 2005 to 2008. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 2687-2691.	1.4	36
136	Worldwide Diversity of <i>Klebsiella pneumoniae</i> That Produce β -Lactamase <i>bla</i> _{KPC-2} Gene1. <i>Emerging Infectious Diseases</i> , 2010, 16, 1349-1356.	2.0	277
137	Molecular Epidemiology of KPC-Producing <i>Klebsiella pneumoniae</i> Isolates in the United States: Clonal Expansion of Multilocus Sequence Type 258. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 3365-3370.	1.4	494
138	Impact of Quinolone Restriction on Resistance Patterns of <i>Escherichia coli</i> Isolated from Urine by Culture in a Community Setting. <i>Clinical Infectious Diseases</i> , 2009, 49, 869-875.	2.9	110
139	Ertapenem Resistance among Extended-Spectrum β -Lactamase-Producing <i>Klebsiella pneumoniae</i> Isolates. <i>Journal of Clinical Microbiology</i> , 2009, 47, 969-974.	1.8	57
140	Evaluation of PCR-Based Testing for Surveillance of KPC-Producing Carbapenem-Resistant Members of the <i>Enterobacteriaceae</i> Family. <i>Journal of Clinical Microbiology</i> , 2009, 47, 3261-3265.	1.8	113
141	First Report on a Hyperepidemic Clone of KPC-3-Producing <i>Klebsiella pneumoniae</i> in Israel Genetically Related to a Strain Causing Outbreaks in the United States. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 818-820.	1.4	156
142	Gram-Negative Bacteremia upon Hospital Admission: When Should <i>Pseudomonas aeruginosa</i> Be Suspected?. <i>Clinical Infectious Diseases</i> , 2009, 48, 580-586.	2.9	60
143	Detection of <i>aac</i> (6)-Ib-cr in KPC-producing <i>Klebsiella pneumoniae</i> isolates from Tel Aviv, Israel. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 718-722.	1.3	34
144	A Multinational Survey of Risk Factors for Infection with Extended-Spectrum β -Lactamase-Producing <i>Enterobacteriaceae</i> in Nonhospitalized Patients. <i>Clinical Infectious Diseases</i> , 2009, 49, 682-690.	2.9	415

#	ARTICLE	IF	CITATIONS
145	Carbapenem-resistant <i>Klebsiella pneumoniae</i> endocarditis in a young adult. <i>International Journal of Infectious Diseases</i> , 2009, 13, e295-e298.	1.5	28
146	Incidence of and Preoperative Risk Factors for <i>Staphylococcus aureus</i> Bacteremia and Chest Wound Infection After Cardiac Surgery. <i>Infection Control and Hospital Epidemiology</i> , 2009, 30, 242-248.	1.0	25
147	Parental <i>Staphylococcus aureus</i> Carriage is Associated With Staphylococcal Carriage in Young Children. <i>Pediatric Infectious Disease Journal</i> , 2009, 28, 960-965.	1.1	33
148	Treatment Options for Multidrug-Resistant <i>Acinetobacter</i> Species. <i>Drugs</i> , 2008, 68, 165-189.	4.9	49
149	Carbapenem-Resistant Enterobacteriaceae. <i>JAMA - Journal of the American Medical Association</i> , 2008, 300, 2911.	3.8	256
150	Analogous oligoacyllysines with distinct antibacterial mechanisms. <i>FASEB Journal</i> , 2008, 22, 2652-2661.	0.2	61
151	Clinical and Economic Impact of Common Multidrug-Resistant Gram-Negative Bacilli. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 813-821.	1.4	519
152	Factors Associated with Candidemia Caused by Non- <i>albicans</i> <i>Candida</i> Species Versus <i>Candida albicans</i> in the Intensive Care Unit. <i>Clinical Infectious Diseases</i> , 2008, 46, 1206-1213.	2.9	226
153	Isolation of Imipenem-Resistant <i>Enterobacter</i> Species: Emergence of KPC-2 Carbapenemase, Molecular Characterization, Epidemiology, and Outcomes. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1413-1418.	1.4	179
154	Plasmid-Mediated qnrB2 and Carbapenemase Gene bla KPC-2 Carried on the Same Plasmid in Carbapenem-Resistant Ciprofloxacin-Susceptible <i>Enterobacter cloacae</i> Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 2962-2965.	1.4	41
155	Predictors of Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Acquisition among Hospitalized Adults and Effect of Acquisition on Mortality. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1028-1033.	1.4	436
156	Dissemination of the CTX-M-25 family β -lactamases among <i>Klebsiella pneumoniae</i> , <i>Escherichia coli</i> and <i>Enterobacter cloacae</i> and identification of the novel enzyme CTX-M-41 in <i>Proteus mirabilis</i> in Israel. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 289-295.	1.3	40
157	High tigecycline resistance in multidrug-resistant <i>Acinetobacter baumannii</i> authors' response. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 60, 178-179.	1.3	6
158	Surveillance Cultures and Duration of Carriage of Multidrug-Resistant <i>Acinetobacter baumannii</i> . <i>Journal of Clinical Microbiology</i> , 2007, 45, 1551-1555.	1.8	154
159	High tigecycline resistance in multidrug-resistant <i>Acinetobacter baumannii</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 59, 772-774.	1.3	212
160	Mortality and delay in effective therapy associated with extended-spectrum β -lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 60, 913-920.	1.3	527
161	First national surveillance of susceptibility of extended-spectrum β -lactamase-producing <i>Escherichia coli</i> and <i>Klebsiella</i> spp. to antimicrobials in Israel. <i>Diagnostic Microbiology and Infectious Disease</i> , 2007, 57, 201-205.	0.8	26
162	Emergence of KPC-2 and KPC-3 in Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Strains in an Israeli Hospital. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 3026-3029.	1.4	226

#	ARTICLE	IF	CITATIONS
163	Molecular and Epidemiologic Study of Polyclonal Outbreaks of Multidrug-Resistant <i>Acinetobacter baumannii</i> Infection in an Israeli Hospital. <i>Infection Control and Hospital Epidemiology</i> , 2007, 28, 945-950.	1.0	56
164	Raising Standards While Watching the Bottom Line Making a Business Case for Infection Control. <i>Infection Control and Hospital Epidemiology</i> , 2007, 28, 1121-1133.	1.0	125
165	Improved antimicrobial peptides based on acyl-lysine oligomers. <i>Nature Biotechnology</i> , 2007, 25, 657-659.	9.4	238
166	Plasmid-Mediated Imipenem-Hydrolyzing Enzyme KPC-2 among Multiple Carbapenem-Resistant <i>Escherichia coli</i> Clones in Israel. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 3098-3101.	1.4	147
167	Clinical and Economic Impact of Bacteremia with Extended-Spectrum β -Lactamase-Producing Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 1257-1262.	1.4	382
168	Antimicrobial resistance and patient outcomes: the hazards of adjustment. <i>Critical Care</i> , 2006, 10, 164.	2.5	21
169	Multidrug-Resistant <i>Pseudomonas aeruginosa</i> : Risk Factors and Clinical Impact. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 43-48.	1.4	527
170	Predictors of Mortality in Patients with Bloodstream Infection Due to Ceftazidime-Resistant <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 1715-1720.	1.4	74
171	Utility of the VITEK 2 Advanced Expert System for Identification of Extended-Spectrum β -Lactamase Production in <i>Enterobacter</i> spp.. <i>Journal of Clinical Microbiology</i> , 2006, 44, 241-243.	1.8	13
172	Endocarditis Caused by Extended-Spectrum β -Lactamase-Producing <i>Klebsiella pneumoniae</i> : Emergence of Resistance to Ciprofloxacin and Piperacillin-Tazobactam during Treatment despite Initial Susceptibility. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 3179-3182.	1.4	57
173	Differential Effects of Levofloxacin and Ciprofloxacin on the Risk for Isolation of Quinolone-Resistant <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 2192-2196.	1.4	50
174	Update on <i>Pseudomonas aeruginosa</i> and <i>Acinetobacter baumannii</i> infections in the healthcare setting. <i>Current Opinion in Infectious Diseases</i> , 2005, 18, 306-313.	1.3	194
175	Multidrug-Resistant <i>Acinetobacter baumannii</i> . <i>Emerging Infectious Diseases</i> , 2005, 11, 22-29.	2.0	223
176	Prior Antimicrobial Therapy and Risk for Hospital-Acquired <i>Candida glabrata</i> and <i>Candida krusei</i> Fungemia: a Case-Case-Control Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 4555-4560.	1.4	134
177	Evaluation of an Accelerated Protocol for Detection of Extended-Spectrum β -Lactamase-Producing Gram-Negative Bacilli from Positive Blood Cultures. <i>Journal of Clinical Microbiology</i> , 2005, 43, 439-441.	1.8	5
178	CTX-M-2 and a New CTX-M-39 Enzyme Are the Major Extended-Spectrum Beta-Lactamases in Multiple <i>Escherichia coli</i> Clones Isolated in Tel Aviv, Israel. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 4745-4750.	1.4	58
179	High Levels of Antimicrobial Coresistance among Extended-Spectrum β -Lactamase-Producing Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 2137-2139.	1.4	140
180	Extended-Spectrum Beta-Lactamases among <i>Enterobacter</i> Isolates Obtained in Tel Aviv, Israel. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 1150-1156.	1.4	71

#	ARTICLE	IF	CITATIONS
181	Antibodies raised against N'-terminal <i>Pseudomonas aeruginosa</i> flagellin prevent mortality in lethal murine models of infection. <i>International Journal of Molecular Medicine</i> , 2005, 16, 165.	1.8	8
182	The Impact of Methicillin Resistance in <i>Staphylococcus aureus</i> Bacteremia on Patient Outcomes: Mortality, Length of Stay, and Hospital Charges. <i>Infection Control and Hospital Epidemiology</i> , 2005, 26, 166-174.	1.0	792
183	Impact of Severity of Illness Bias and Control Group Misclassification Bias in Case-Control Studies of Antimicrobial-Resistant Organisms. <i>Infection Control and Hospital Epidemiology</i> , 2005, 26, 342-345.	1.0	43
184	The Case-Case-Control Study Design: Addressing the Limitations of Risk Factor Studies for Antimicrobial Resistance. <i>Infection Control and Hospital Epidemiology</i> , 2005, 26, 346-351.	1.0	142
185	Fluoroquinolones Protective against Cephalosporin Resistance in Gram-negative Nosocomial Pathogens. <i>Emerging Infectious Diseases</i> , 2004, 10, 94-99.	2.0	23
186	Reference Group Choice and Antibiotic Resistance Outcomes. <i>Emerging Infectious Diseases</i> , 2004, 10, 1125-1128.	2.0	104
187	Hospital-Acquired Infective Endocarditis: Should the Definition be Broadened?. <i>Clinical Infectious Diseases</i> , 2004, 38, 843-850.	2.9	73
188	Association Between Carriage of <i>Streptococcus pneumoniae</i> and <i>Staphylococcus aureus</i> in Children. <i>JAMA - Journal of the American Medical Association</i> , 2004, 292, 716.	3.8	261
189	The Magnitude of the Association between Fluoroquinolone Use and Quinolone-Resistant <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> May Be Lower than Previously Reported. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 1934-1940.	1.4	36
190	Reply to Cicalini et al.. <i>Clinical Infectious Diseases</i> , 2004, 39, 1085-1085.	2.9	33
191	Glycopeptides Are No More Effective than β -Lactam Agents for Prevention of Surgical Site Infection after Cardiac Surgery: A Meta-analysis. <i>Clinical Infectious Diseases</i> , 2004, 38, 1357-1363.	2.9	134
192	Should third-generation cephalosporins be avoided against AmpC-inducible Enterobacteriaceae?. <i>Clinical Microbiology and Infection</i> , 2004, 10, 84-85.	2.8	32
193	Epidemiological interpretation of antibiotic resistance studies – what are we missing?. <i>Nature Reviews Microbiology</i> , 2004, 2, 979-983.	13.6	88
194	Studies of Bloodstream Infection Outcomes: Reading Between the Lines. <i>Infection Control and Hospital Epidemiology</i> , 2003, 24, 884-886.	1.0	12
195	Comparison of Mortality Associated with Methicillin-Resistant and Methicillin-Susceptible <i>Staphylococcus aureus</i> Bacteremia: A Meta-analysis. <i>Clinical Infectious Diseases</i> , 2003, 36, 53-59.	2.9	1,782
196	The Impact of Antimicrobial Resistance on Health and Economic Outcomes. <i>Clinical Infectious Diseases</i> , 2003, 36, 1433-1437.	2.9	504
197	Treatment with a Broad-Spectrum Cephalosporin versus Piperacillin-Tazobactam and the Risk for Isolation of Broad-Spectrum Cephalosporin-Resistant Enterobacter Species. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 1882-1886.	1.4	46
198	Occurrence and Phenotypic Characteristics of Extended-Spectrum β -Lactamases among Members of the Family Enterobacteriaceae at the Tel-Aviv Medical Center (Israel) and Evaluation of Diagnostic Tests. <i>Journal of Clinical Microbiology</i> , 2003, 41, 155-158.	1.8	49

#	ARTICLE	IF	CITATIONS
199	Adverse Clinical and Economic Outcomes Attributable to Methicillin Resistance among Patients with <i>Staphylococcus aureus</i> Surgical Site Infection. <i>Clinical Infectious Diseases</i> , 2003, 36, 592-598.	2.9	860
200	Clinical Implications of Varying Degrees of Vancomycin Susceptibility in Methicillin-Resistant <i>Staphylococcus aureus</i> Bacteremia. <i>Emerging Infectious Diseases</i> , 2003, 9, 657-664.	2.0	42
201	Fluoroquinolones and the Risk for Methicillin-resistant <i>Staphylococcus aureus</i> in Hospitalized Patients. <i>Emerging Infectious Diseases</i> , 2003, 9, 1415-1422.	2.0	312
202	Antibacterial Properties of Dermaseptin S4 Derivatives with In Vivo Activity. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 689-694.	1.4	130
203	Effects of Antibiotics on Nosocomial Epidemiology of Vancomycin-Resistant Enterococci. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 1619-1628.	1.4	148
204	Control of Group Selection Importance in Studies of Antimicrobial Resistance: Examples Applied to <i>Pseudomonas aeruginosa</i> , Enterococci, and <i>Escherichia coli</i> . <i>Clinical Infectious Diseases</i> , 2002, 34, 1558-1563.	2.9	163
205	Health and Economic Outcomes of the Emergence of Third-Generation Cephalosporin Resistance in Enterobacter Species. <i>Archives of Internal Medicine</i> , 2002, 162, 185.	4.3	244
206	Health and Economic Outcomes of Vancomycin-Resistant Enterococci. <i>Archives of Internal Medicine</i> , 2002, 162, 2223.	4.3	211
207	Antecedent Treatment with Different Antibiotic Agents as a Risk Factor for Vancomycin-Resistant Enterococcus. <i>Emerging Infectious Diseases</i> , 2002, 8, 802-807.	2.0	143
208	Methodological Principles of Case-Control Studies That Analyzed Risk Factors for Antibiotic Resistance: A Systematic Review. <i>Clinical Infectious Diseases</i> , 2001, 32, 1055-1061.	2.9	246
209	Clinical Isolation and Resistance Patterns of and Superinfection with 10 Nosocomial Pathogens after Treatment with Ceftriaxone versus Ampicillin-Sulbactam. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 275-279.	1.4	21
210	Parallel Analysis of Individual and Aggregated Data on Antibiotic Exposure and Resistance in Gram-Negative Bacilli. <i>Clinical Infectious Diseases</i> , 2001, 33, 1462-1468.	2.9	153
211	Risk Factors for Emergence of Resistance to Broad-Spectrum Cephalosporins among Enterobacter spp. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 2628-2630.	1.4	153
212	Prolonged Antibiotic Prophylaxis After Cardiovascular Surgery and Its Effect on Surgical Site Infections and Antimicrobial Resistance. <i>Circulation</i> , 2000, 101, 2916-2921.	1.6	503
213	SME-Type Carbapenem-Hydrolyzing Class A β -Lactamases from Geographically Diverse <i>Serratia marcescens</i> Strains. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 3035-3039.	1.4	123
214	Risk Factors for Recovery of Ampicillin-Sulbactam-Resistant <i>Escherichia coli</i> in Hospitalized Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 1004-1009.	1.4	58
215	Clinical Significance and Antibiotic Resistance Patterns of <i>Lemnora</i> spp., an Emerging Nosocomial Pathogen. <i>Journal of Clinical Microbiology</i> , 2000, 38, 3036-3038.	1.8	16
216	Emergence of Antibiotic-Resistant <i>Pseudomonas aeruginosa</i> : Comparison of Risks Associated with Different Antipseudomonal Agents. <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 1379-1382.	1.4	497

#	ARTICLE	IF	CITATIONS
217	The Association Between Antecedent Vancomycin Treatment and Hospital-Acquired Vancomycin-Resistant Enterococci. Archives of Internal Medicine, 1999, 159, 2461.	4.3	129
218	Risk Factors for Nosocomial Candiduria Due to <i>Candida glabrata</i> and <i>Candida albicans</i> . Clinical Infectious Diseases, 1999, 29, 926-928.	2.9	86
219	Health and Economic Outcomes of Antibiotic Resistance in <i>Pseudomonas aeruginosa</i> . Archives of Internal Medicine, 1999, 159, 1127.	4.3	298
220	Epidemiology and Clinical Outcomes of Patients with Multiresistant <i>Pseudomonas aeruginosa</i> . Clinical Infectious Diseases, 1999, 28, 1128-1133.	2.9	161
221	Nosocomial Superinfections with Gram-Negative Pathogens and Quinolone Resistance after Treatment with Ciprofloxacin vs Ofloxacin. Drugs, 1999, 58, 128-129.	4.9	0
222	Failure of Quality Control Measures To Prevent Reporting of False Resistance to Imipenem, Resulting in a Pseudo-Outbreak of Imipenem-Resistant <i>Pseudomonas aeruginosa</i> . Journal of Clinical Microbiology, 1998, 36, 595-597.	1.8	15
223	Imipenem-Resistant <i>Pseudomonas aeruginosa</i> : Risk Factors and Antibiotic Susceptibility Patterns. Clinical Infectious Diseases, 1997, 25, 1094-1098.	2.9	159